What is Martin Shkreli Net Worth 2023: Bio, Investing, Fund, And More

What is Martin Shkreli Net Worth 2023 Bio, Investing, Fund, And More

Alright, folks, let’s dive into the wild world of Martin Shkreli net worth! You might remember this guy as the Pharma Bro who stirred up a whole lot of controversy a while back. Well, love him or hate him, there’s no denying he made quite a splash in the financial world. We’re here to spill the beans on just how much dough he’s got stashed away. 

So, grab your popcorn and get ready to find out what’s in the bank for this infamous figure!

Quick Facts

InformationDetails
Real NameMartin Shkreli
Popular NamePharma Bro
GenderMale
Birth DateMarch 17, 1983
Age40 years old
ParentsAlbanian immigrants
SiblingsTwo sisters and one brother
Birth PlaceBrooklyn, New York, U.S.
NationalityAmerican
EthnicityAlbanian
EducationHunter College High School, Baruch College (BBA degree)
Marital StatusSingle
Sexual OrientationNot specified
Wife/SpouseN/A
ChildrenN/A
DatingN/A
Net Worth$70 Million as of 2023
Source of WealthInvestor, fintech developer, YouTuber, former hedge fund manager and biotech founder
HeightNot specified
WeightNot specified

What is Net Worth of Martin Shkreli 2023?

What is Net Worth of Martin Shkreli 2023

As of September 28, 2023, Martin Shkreli’s estimated net worth stands at $70 million. This figure is a result of his ownership of approximately 1,765,168 shares of Travere Therapeutics Inc (TVTX) stock, which are valued at over $15 million.

However, it’s important to note that Shkreli’s net worth has seen significant fluctuations over the years due to his legal troubles and penalties.

Martin Shkreli Salary

After serving almost seven years in prison for securities fraud, Martin Shkreli now earns a monthly salary of $2,500 as a consultant for a law firm.

He currently resides with his sister in Queens, New York, as reported by the US Probation Office in May 2023.

Martin Shkreli Overview and Wiki

Martin Shkreli Overview and Wiki

Early Life

Martin Shkreli was born on March 17th, 1983, in Brooklyn, New York, USA. His parents were immigrants from Albania and Croatia who worked as janitors.

Shkreli has described his upbringing as lower-middle-class and credits his success to his drive and intelligence.

Education

Shkreli attended Hunter College High School in Manhattan before earning a Bachelor of Business Administration degree from Baruch College.

Despite not having a medical degree, Shkreli became involved in the pharmaceutical industry through his hedge fund investments and co-founded several drug companies.

Career and Awards

After college, Martin Shkreli began his career as a financial analyst at the investment bank Cramer, Berkowitz & Co. In 2006, he founded his own hedge fund, Elea Capital Management, which was named after his grandfather.

In 2011, he founded another hedge fund, MSMB Capital Management, which was shut down after he was sued by Retrophin for using its assets to pay off personal debts.

In 2012, Shkreli became the CEO of Retrophin, a biopharmaceutical company that focuses on developing treatments for rare diseases.

However, he was fired from the company in 2014 due to alleged financial irregularities. The following year, he gained notoriety as the CEO of Turing Pharmaceuticals when he raised the price of Daraprim by over 5,000%.

In 2017, Shkreli was convicted of securities fraud and conspiracy for his activities at MSMB Capital Management and Retrophin. He was sentenced to seven years in prison and ordered to pay up to $7.4 million in fines.

In addition, he was fined $64.6 million in a civil case to be repaid to victims.

As of now, Martin Shkreli interacts with people online by live on YouTube several times a week. He talks about how he started investing and dealing in stocks and crypto assets, giving advice and thoughts on what he learned.

Read more: TOP 30+ Richest Youtubers In The World 2023

Personal Life

Despite his high-profile legal battles and controversies surrounding his business practices, Martin Shkreli has remained relatively private about his personal life. He has not been married and is not known to have any children.

Social Media Accounts

Martin Shkreli News 2023

Here is a list of Martin Shkreli news headlines from 2023:

  • January 23: FTC asks judge to hold ‘pharma bro’ Martin Shkreli in contempt of court for forming new drug firm
  • February 10: Martin Shkreli: I’m not in contempt over drug industry ban

May 23: Pharma Bro Martin Shkreli Making $2,500 a Month in NYC

FAQs about Martin Shkreli

FAQs about Martin Shkreli

What is Martin Shkreli’s net worth in 2023?

Martin Shkreli’s net worth is unclear since he is currently serving time in prison. However, prior to his conviction, he had a net worth of around $70 million.

How did Martin Shkreli make his money?

Shkreli made his money through his hedge fund investments and co-founding several pharmaceutical companies, including Retrophin and Turing Pharmaceuticals.

What is Martin Shkreli’s salary in 2023?

Since Shkreli is currently serving time in prison, his salary is unclear.

What is Martin Shkreli most known for?

Martin Shkreli is most known for raising the price of Daraprim, an antip arasitic drug, by 5,455% after his company, Turing Pharmaceuticals, acquired the manufacturing license for the drug.

He is also known for his conviction on securities fraud and conspiracy charges unrelated to the Daraprim controversy.

What has Martin Shkreli been doing since his conviction?

Since his conviction in 2017, Martin Shkreli has been serving his sentence in prison. There have been no major updates on his activities or legal situation as of September 2023.

Also see:

Conclusion

Martin Shkreli’s life and career have been marked by significant highs and lows. From co-founding successful hedge funds and pharmaceutical companies to facing legal troubles and public backlash, his journey is a testament to the unpredictable nature of the business world.

As of 2023, Shkreli continues to navigate his path, maintaining an active presence in the public eye and managing his financial affairs amidst ongoing legal challenges.

Leave a Reply

Your email address will not be published. Required fields are marked *